MET and hepatocellular carcinoma: Cabozantinib, an mTKI that inhibits several kinases – including MET, AXL, RET, FLT3, and VEGFR2 - was approved for use in patients with HCC who had been previously treated with sorafenib based on results from the phase III CELESTIAL trial.